Small Batches. Big Impact. Orphan-Scale Expertise.

At Mika Biologics, we believe some of the most important medicines in the world aren’t made for millions—they’re made for the few. Rare diseases, often affecting just dozens or hundreds of patients, carry profound unmet needs. Orphan drugs targeting these conditions are lifelines: therapies that may transform or even save lives where no treatments exist.

Yet, developing rare biologics presents unique challenges: small patient populations, limited funding, small-batch clinical needs, and therapies often deemed “too complex” or “too low priority” by mainstream CDMOs.

This is where Mika thrives. We are a specialist microbial & phage-first CDMO, purpose-built to support rare disease innovators with orphan-scale GMP runs, flexible timelines, and technical mastery of difficult biologics.

We don’t treat rare as an exception—we treat it as our core mission.

What Rare Disease & Orphan Drug Companies Value

Companies and foundations working in rare disease face unique pressures. They value CDMO partners who:

1. Respect Small Scale

Most CDMOs are built around economies of scale. Rare disease programs don’t need 10,000 L of product—they need grams to kilograms. Mika’s 1–2000 L microbial capacity is optimized for orphan-scale GMP runs.

2. Prioritize the “Few”

For us, patients with rare diseases are not low priority—they are our priority. Our systems are agile enough to treat these programs with the urgency and respect they deserve.

3. Solve Technical Challenges Others Avoid

Many orphan biologics are enzymes, cytokines, or niche proteins that misfold or aggregate. Big CDMOs decline these projects. Mika embraces them with proprietary folding/refolding workflows.

4. Enable Faster INDs

Rare disease innovators need speed to clinic to validate therapies and attract funding. Microbial systems move faster, with weeks instead of months from gene to protein.

5. Provide Regulatory Guidance

Orphan drug developers often lack in-house regulatory teams. Mika provides CMC strategy, comparability studies, and IND/CTA support tailored to rare disease pathways.

Current Technical Needs in Rare Disease & Orphan Drugs

1. Enzyme Replacement Therapies (ERTs)

• Lysosomal enzymes for metabolic/storage disorders.
• Require solubility optimization, activity validation, and stability formulation.

2. Rare Cytokines & Growth Factors

• ILs, interferons, and colony-stimulating factors.
• Often misfold in bacterial systems—Mika specializes in refolding & activity assays.

3. Orphan Plasmids & Vectors

• For gene therapies and mRNA vaccines targeting rare conditions.
• Endotoxin-free plasmids are essential.

4. Small-Batch GMP

• Phase I/II trials requiring 1–50 L runs.
• Big CDMOs see this as inefficient; Mika sees it as mission-critical.

5. Stability & Formulation

• Rare biologics often need special formulations for stability in low-volume supply chains.

6. Endotoxin-Free Manufacturing

• ClearColi® systems and engineered strains for clean biologics.

7. Rare Disease Regulatory Strategy

• Orphan drug designation, accelerated approval, compassionate use programs.

Innovation in Rare Disease Today

Mika is aligned with the major innovation drivers in rare disease R&D:

• Gene Therapies – plasmid DNA, CRISPR proteins, and viral scaffold proteins.
• Protein Replacement – microbial enzymes and cytokines delivered as biologics.
• Oncology-Orphan Crossovers – rare cancers treated with immune biologics.
• mRNA & DNA Vaccines – microbial plasmids and VLPs for ultra-rare infectious diseases.
• Engineered Microbiome Therapies – probiotics delivering enzymes or cytokines.
• Nanoparticles – biologic scaffolds for targeted delivery in rare metabolic disorders.

How Mika Delivers Value to Rare Disease Programs

1. Orphan-Scale GMP Runs

Flexible GMP runs (1–2000 L) designed for grams-to-kilograms—not blockbuster scale.

2. Technical Mastery of Orphan Biologics

We thrive on “hard” proteins: cytokines, enzymes, scaffolds.

3. Regulatory Guidance for Orphans

We provide CMC packages, comparability studies, and orphan designation support.

4. Faster Path to Clinic

Microbial systems (and cell-free extracts) provide rapid prototyping and production.

5. True Partnership

We collaborate with rare disease companies and foundations as partners, not vendors.

Technical Capabilities That Matter to Rare Disease Innovators

• Fermentation: 1–2000 L, with partners up to 20,000 L.
• Downstream: centrifugation, TFF, chromatography, lyophilization.
• Analytics: HPLC/UHPLC, ELISA, activity assays, mass spectrometry.
• Refolding Suites: specialized for cytokines/enzymes.
• Quality Systems: FDA/EMA-compliant, IND-ready.

Case Examples

• Rare Disease Foundation – lysosomal enzyme produced at 50 L GMP for Phase I, with activity validated in cell-based assays.
• Biotech Startup – IL-7 manufactured at orphan scale, enabling successful IND.
• Gene Therapy Innovator – endotoxin-free plasmids produced for rare metabolic disorder trial.
• Diagnostics Pioneer – specialty enzyme produced for rare diagnostic kits.

Top 10 Technical FAQ for Rare Disease & Orphan Drugs

1. What batch sizes does Mika support?
   1 L → 2,000 L in-house microbial (bench/pilot → cGMP). Our sweet spot is 10–200 L IND/Phase I/II orphan-scale, with tech runs at 1–5 L for rapid DOE. We run single-use upstream trains, PAT (in-situ Raman/DO/CO₂), and closed transfer to right-size COGs for micro-lots. Optional continuous harvest, high-cell-density fed-batch, and ATF-style cell retention for secretion strains.
2. Can Mika produce lysosomal enzymes?
   Yes—microbial expression with inclusion-body capture followed by chaotrope solubilization and redox-guided refolding (GSH/GSSG gradients, arginine/osmolytes, mixed micelles). For human-like glycans/M6P targeting (needed for ERT uptake), we support post-expression chemoenzymatic glyco-remodeling via partners (endoglycosidase trimming + in-vitro glycosyltransfer), PEGylation or Fc-fusion alternatives where appropriate, and ligand-decorated nanoparticles as targeting proxies in early phases. We qualify with activity assays, uptake in M6PR+ cell lines, and secondary LC-MS intact mass/peptide maps.
3. How do you handle very small clinical supply needs?
   Gram-to-low-kg outputs using micro-GMP trains, minimizing dead-volume and hold times. We design Phase-appropriate specs (QbD-lite) and freeze intermediates (e.g., post-capture bulk DS) to create modular resupply. Campaign gapping lets you re-enter quickly without full re-validation. Stability-indicating methods and bracketing keep testing lean while maintaining IND robustness.
4. What about rare cytokines (ILs, IFNs, GM-CSF)?
   We specialize in hard-to-fold cytokines: inclusion-body strategies with HT refold screening (96-well matrices of pH, redox pairs, kosmotropes, detergents), on-column refolding, and secretion-optimized strains when feasible. Downstream typically uses IEX/HIC → polishing (SEC or mixed-mode) with endotoxin control ≤0.1 EU/mg for parenterals. Orthogonal potency (receptor-cell bioassays) and SPR/BLI receptor-binding kinetics ensure MOA relevance.
5. Does Mika offer plasmid DNA production?
   Yes—endotoxin-managed pDNA using LPS-minimized hosts (e.g., ClearColi®) or conventional E. coli with aggressive endotoxin clearance. We deliver >90–95% supercoiled, low residual HCD/HCP/gDNA, and RNase-free profiles. Release includes A260/280, ccc % by CE, endotoxin (rFC/LAL), residual solvents/surfactants, and sterility. Scale bands: 0.5–20 g per lot with campaignability for more.
6. How does Mika handle stability for rare biologics?
   Formulation-first: screen buffers (histidine/acetate/citrate), excipients (trehalose/sucrose/arginine/polysorbates/poloxamers), and antioxidants. Lyophilization with Tg′/Tc mapping, DVS, and MTM-optimized cycles (primary/secondary dry times bounded by collapse temperature). Accelerated/long-term ICH-aligned studies feed stability-indicating analytics (icIEF for charge, SEC-MALS for aggregation, RP-HPLC for variants, LC-MS for PTMs).
7. Can Mika help with Orphan Drug Designation (ODD)?
   Yes—regulatory writing support (non-clinical rationale, prevalence calculations, medical plausibility) and CMC sections aligned to ICH Q5/Q6B/Q8/Q9/Q10. We prep comparability protocols (process tweaks within orphan programs), CTD Module 3 content, and phase-appropriate control strategies. We’ll coordinate with your regulatory counsel for filings to FDA/EMA.
8. How does QC work for orphan proteins with limited material?
   We build orthogonal, material-sparing methods: icIEF/cIEF, SEC-MALS, RP-HPLC mapping, intact/peptide LC-MS, host-contaminant panels (HCP ELISA, residual DNA qPCR, residual endotoxin via rFC). Potency via cell-based bioassays (STAT phosphorylation readouts, reporter lines) or surrogate binding (SPR/BLI) when cells are impractical. Method lifecycle: development → phase-lock → validation at Pivotal.
9. What is Mika’s advantage over big CDMOs?
   We’re engineered for micro-batches and complexity: fast tech transfer, micro-GMP footprint, scientist-led troubleshooting, and priority in scheduling. Our digital batch records, real-time release analytics, and micro-lot logistics de-risk timelines. Where majors push you into mammalian defaults, we extract microbial and hybrid routes that are faster, cheaper, and orphan-scale appropriate.
10. How fast can Mika deliver IND-ready material?
    Program-dependent, but 8–20 weeks is typical from sequence-final to DS/DP when leverageable platforms exist (host/vector, capture resin, analytics). Critical path: MCB/WCB, plasmid supply, refold/formulation screening, potency method readiness. Risk-buy options (resins, media, excipients) and parallelization (method + process in lockstep) compress the path.

Edge Cases We Routinely Handle

• Ultra-rare lots: Sub-gram to multi-gram tox/PD material with full traceability.
• High endotoxin risk: Endotoxin-retentive flowpaths, AEX/rFC-driven reduction, phase-appropriate specing.
• Immunogenic epitopes: Deimmunization scans, T-cell epitope risk assessment, targeted glyco-masking/PEGylation via partners.

Niche Modalities & Add-Ons

• Cell-free protein synthesis (CFPS): Rapid micro-lots for screening and tox without full cell-bank timelines.
• Enzyme–nanoparticle hybrids: Cytokines/enzymes adsorbed/encapsulated in GRAS-grade carriers for stability or targeting feasibility studies.
• Mixed-mode polishing for cystine-rich proteins that defeat classical IEX/HIC splits.
• Smart excipient stacks: Trehalose–arginine–histidine systems tuned by design-of-experiments to suppress aggregation at high concentration.

Analytics Deep Dive (Phase-Appropriate)

• Identity/heterogeneity: Intact MS, reduced/non-reduced peptide maps, icIEF, CE-SDS.
• Potency/MOA: Receptor-cell bioassays (e.g., STAT1/3), SPR/BLI kinetics (kon/koff/KD), and functional enzyme turnover (kcat/Km).
• Impurities: HCP (ELISA/msPAQ), residual DNA, endotoxin (rFC), host lipids, detergents/solvents.
• Stability: Thermal ramps (nanoDSF/DSC), forced degradation (oxidation/deamidation), photostress, freeze–thaw.

The Near Future of Orphan Biologics (What We’re Building In)

• Distributed Orphan-GMP: Modular micro-plants near clinics; same QMS, digital twins, mirrored SOPs.
• AI-guided refold & formulation: ML models predicting solubility/refold yields and excipient stacks from sequence/structure.
• PAT-heavy DS/DP: Inline UV/MALS/Raman, trending to real-time release for micro-lots.
• Hybrid routes: Microbial→glyco-remodel or microbial core→LNP delivery for certain targets when mammalian isn’t phase-efficient.
• Patient-aligned economics: COGs designed for foundation/consortium funding and named-patient access where applicable.

Closing Statement

Rare diseases may be “rare,” but for those affected, they are everything. Developing orphan drugs is not about scale—it’s about impact.

At Mika Biologics, we make rare biologics possible. With microbial-first mastery, orphan-scale GMP systems, and regulatory fluency, we deliver the therapies that other CDMOs overlook.

We don’t treat rare as an exception—we treat it as our mission. We are the best rare disease & orphan drug CDMO in the U.S., the world, and the galaxy.

Mika Biologics. Microbial Systems. Immune Innovation. Beyond the Cell.

Mika Biologics is ready for your projects!

Email our team at info@mikabiologics.com